In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melinta Therapeutics Inc.

Latest From Melinta Therapeutics Inc.

Daiichi Sankyo’s AML Drug Among Nine CHMP Hopefuls

Will regulators in the EU follow their US counterparts in requiring more efficacy data for Daiichi Sankyo’s acute myeloid leukemia drug quizartinib, which is already approved in Japan?

Drug Review Approvals

Promising Shionogi Candidate Moves Ahead In Gram-Negative Pneumonia

Novel Shionogi antibiotic candidate set to move ahead following positive results in Gram-negative pneumonia, where resistance and unmet needs remain critical factors.
Infectious Diseases Clinical Trials

Medicare New Technology Add-On Payment Awards For Hospital Drugs On The Rise

Eight inpatient prescription drugs are deemed eligible for supplemental payments in 2020, a big increase from years past, based on a review of US Medicare's new technology add-on payment approvals for prescription drugs since 2011. 

Medicare Reimbursement

WHO’s Expanded Essential Drugs List Includes High-Priced Anticancers & Immunomodulators

The World Health Organization has published its latest list of essential medicines, with a number of expensive drugs for cancers and autoimmune disorders figuring for the first time. The organization says that all patients should have access to life-saving medicines regardless of their ability to pay, but the pharmaceutical industry says this should be done with caution to avoid undermining innovation.

International Market Access
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Rib-X Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Melinta Therapeutics Inc.
  • Senior Management
  • Peter Milligan, CFO
    Sue Cammarata, MD, CMO
    Ryan Lococo, VP, Corp. Dev. & Strategy & CBO
    Erin Duffy, PhD, CSO
  • Contact Info
  • Melinta Therapeutics Inc.
    Phone: (203) 624-5606
    300 George St., Ste. 301
    New Haven, CT 06511-6663
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register